Baptist Health Cancer Care

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

Minesh Mehta, MD, discusses positive findings from the phase 3 METIS trial investigating TTFields therapy for brain metastases in NSCLC.

The novel PPAR-α inhibitor TPST-1120 shows promise for solid tumors, including renal cell carcinoma, as monotherapy and in combination with nivolumab.

In an interview with Targeted Oncology, Manmeet Ahluwalia, MD, MBA, FASCO, discussed the Cancer Moonshot program, its progress, and the next steps.

Guenther Koehne, MD, PhD, highlights the importance of and the key takeaways from the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies.

In an interview with Targeted Oncology, Manmeet S. Ahluwalia, MD, provided insights into his personal career and goals and the transformative potential of oncology.

In an interview with Targeted Oncology, Rohan Garje, MD, discussed how mutations such as TP53, RB1, and PTEN impact overall survival in patients with metastatic prostate cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.

Bruno R. Bastos, MD, discusses the future following a study assessing the changes among patients with renal cell carcinoma who were treated with nivolumab and TPST-1120.

In an interview with Targeted Oncology, Eric Schroeder, MD, discussed the transformative shift that the landscape of ovarian cancer treatment has undergone in recent years.

In an interview for Cholangiocarcinoma Awareness Day, Domenech Asbun, MD, discussed how the management of cholangiocarcinoma continues to evolve and addressed unmet needs in early detection and systemic therapy.

Eric Schroeder, MD, discusses how treatments for patients with ovarian cancer have evolved in recent years.

For Gallbladder Cancer Awareness Month, Horacio J. Asbun, MD, and Domenech Asbun, MD, shared their thoughts and strategies for treating patients with this disease from the surgical and clinical sides.

Federico Albrecht, MD, discusses the challenging case of a 67-year-old heavy smoker who presented with small cell lung cancer.

In an interview with Targeted Oncology, Bruno Bastos, MD, discussed how TPST-1120 can help address limited treatment options for patients with advanced renal cell carcinoma beyond immunotherapy and anti-VEGF tyrosine kinase inhibitors.

In an interview with Targeted Oncology, Michael Zinner, MD, explored the scientific challenges and breakthroughs shaping the landscape of oncology care in the context of World Cancer Day.

Federico Albrecht, MD, discusses Miami Cancer Institute's specific protocol for hospitalized patients with small cell lung cancer.

In an interview with Targeted Oncology, Guenther Koehne, MD, discussed the latest research surrounding autologous and allogeneic stem cell transplants.

Bruno R. Bastos, MD, discusses findings from a study which assessed the pharmacodynamic and radiographic changes among patients with renal cell carcinoma who were treated with the combination of nivolumab and TPST-1120.

Federico Albrecht, MD, discusses the standard practice on testing for a patient with small cell lung cancer at Miami Cancer Institute.

In an interview with Targeted Oncology, Guenther Koehne, MD, provides a comprehensive overview of the dynamic landscape and evolving strategies in immunotherapy for hematologic malignancies.

In an interview with Targeted Oncology, Louise Morrell, MD, discussed the landscape of genetic testing in oncology and the latest advancements in the field.

In an interview with Targeted Oncology, Naomi Dempsey, MD, provided insight into the benefits of endocrine therapy in patients with breast cancer and the implications of findings from this research.

In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed data from a quality improvement initiative identifying issues for health care professionals and patients with HER2-positive breast cancer.

Manmeet Ahluwalia, MD, discusses the future initiatives of the Cancer Moonshot program.

Manmeet Ahluwalia, MD, discusses the implications of the Cancer Moonshot program for community oncologists.

In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.

Manmeet Ahluwalia, MD, discusses the progress and initiatives of the Cancer Moonshot program.